- Home
- CLYM
CLYM
CLIMB BIO INC
as 12-20-2024 3:33pm EST
Stocks
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WELLESLEY HILLS |
| Market Cap: | 201.7M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 264.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $11.55 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest CLIMB BIO INC News
CLYM Breaking Stock News: Dive into CLYM Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Climb Bio to be Added to the Nasdaq Biotechnology Index
GlobeNewswire
a month ago
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
a month ago
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
GlobeNewswire
2 months ago
Climb Bio to Present at Upcoming Investor Conferences
GlobeNewswire
2 months ago
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
GlobeNewswire
2 months ago
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
GlobeNewswire
3 months ago
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Compare CLYM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLYM CLIMB BIO INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.